相关实验视频

Updated: Jul 13, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

针对心脏瑞诺丁受体向治疗的大型高通量屏幕

Roman Nikolaienko¹, Elisa Bovo¹, Jonathan C Solberg²

¹Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.

The Journal of biological chemistry

|November 19, 2025

概括

研究人员发现了调节受体 (RyR) 通道的化合物,通过减少病理性泄漏,潜在地治疗心力衰竭和神经退行症等疾病.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

瑞诺丁受体 (RyRs) 控制细胞内从内/细胞网膜释放.
病理性泄漏的RyRs导致持续升高的水平,与心力衰竭,心律失常和神经退行有关.

研究的目的:

为了识别小分子调节器的氨酸受体 (RyR) 释放通道.
寻找可以全调节RyR.R.病理性泄漏状态的化合物.

主要方法:

使用高通量选 (HTS) 与光寿命 (FLT) 检测的福斯特共振能量转移 (FRET).
在病理条件下的心脏SR膜中对RyR2进行了50,000个化合物库的选.
通过FRET剂量反应试验和 [3H] 氨酸结合试验验验证的结果.

主要成果:

确定了603种化合物,可重复性地改变FRET信号.
验证了83种化合物,其中10种化学支架显示出可取的模素结合.
六种化合物显示RyR2活性降低,异醇组显示治疗潜力.

结论:

发现了新型的小分子,可全调节RyR2,准病理性泄漏.
这些化合物,特别是那些含有异醇部分的化合物,代表了对RyR相关疾病的潜在治疗方法.

关键词:

生物传感器生物传感器通道中的.细胞内释放的.泄漏是因为泄漏.卡尔莫杜林 (CaM) 是一种这是心肌细胞 (cardiomyocyte).药物查对药物进行查.光共振能量转移 (FRET) 是一种高通量选 (HTS) 是一种高通量选.艾索克萨 (ISOXAZOL) 是一种

更多相关视频

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...